MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 19, ...

MannKind Corporation (NASDAQ:MNKD) is one of the 11 Best US Stocks to Invest in Under $5. MannKind Corporation (NASDAQ:MNKD) ...

MannKind to Present at Upcoming Investor Conferences. DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the ...

It took 10 years and $1 billion for MannKind Corp. in Valencia to get its breakthrough inhaled-insulin drug approved by U.S. regulators.

Is the dreamboat envisioned by MannKind Corp. turning into something more akin to the Titanic? I've been a proponent of the biotech for quite a while, but it's hard to remain positive about ...

Hours after MannKind Corp. announced on Tuesday that Sanofi had pulled out of an agreement to license its Afrezza inhaled insulin, a MannKind executive said the Valencia company does not plan to ...

What:Shareholders of inhaled insulin maker MannKind Corporation are having a rough day. The company's stock is down more than 26% as of 12:30 p.m. EST Tuesday after MannKind reported its first ...

Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 20203Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020$181.1 million of Cash, Cash ...

What happened Shares of MannKind Corporation (NASDAQ: MNKD) were down 13.9% as of 3:31 p.m. EDT on Monday. The drop followed a 23% plunge on Friday.

MannKind Corporation beats analysts on earnings and revenue in Q2 2023, with a year-over-year increase of 157.3% in revenue. Strong demand for Afrezza and Tyvaso DPI contributes to revenue growth.

View MannKind Corporation MNKD stock quote prices, financial information, real-time forecasts, and company news from CNN.